公开(公告)号：US20230132750A1

公开(公告)日：2023-05-04

申请号：US17995685

申请日：2021-04-08

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jinil HAN ,  Yun Young LEE

IPC: C12Q1/6886

Abstract: The present invention relates to a composition, a kit, a nucleic acid chip, and a method capable of diagnosing colorectal cancer, rectal cancer, or colorectal adenoma by detecting the methylation level of CpG sites in a GLRB gene. Accordingly, colorectal cancer, rectal cancer, or colorectal adenoma can be diagnosed not only accurately and quickly, but also at an early stage.

公开(公告)号：US10655187B2

公开(公告)日：2020-05-19

申请号：US16155220

申请日：2018-10-09

Applicant: GENCURIX INC.

Inventor： Young Kee Shin ,  Young-Deug Kim ,  En Sel Oh ,  Jun Young Choi ,  Sang Rea Cho

IPC: C07H21/04 ,  C12Q1/68 ,  C12Q1/6886

Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

公开(公告)号：US10304561B2

公开(公告)日：2019-05-28

申请号：US15582330

申请日：2017-04-28

Applicant: ABION, INC. ,  GENCURIX INC.

Inventor： Young Kee Shin ,  Mi J. Kwon ,  En Sel Oh ,  Yong H. In ,  Sang S. Koh

IPC: C12Q1/68 ,  G16B25/00 ,  C12Q1/6813 ,  C12Q1/6851

Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.

公开(公告)号：US20180216199A1

公开(公告)日：2018-08-02

申请号：US15938633

申请日：2018-03-28

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q1/68 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy.Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.

公开(公告)号：US20180216198A1

公开(公告)日：2018-08-02

申请号：US15938331

申请日：2018-03-28

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

IPC: C12Q1/6886

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy.Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient, and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.

公开(公告)号：US20180068057A1

公开(公告)日：2018-03-08

申请号：US15582330

申请日：2017-04-28

Applicant: REFERENCEBIOLABS CO., LTD. ,  GENCURIX INC.

Inventor： Young Kee Shin ,  Mi J. Kwon ,  En Sel Oh ,  Yong H. In ,  Sang S. Koh

IPC: G06F19/20 ,  C12Q1/68

CPC classification number: G06F19/20 ,  C12Q1/6813 ,  C12Q1/6851 ,  C12Q2600/166 ,  C12Q2545/113 ,  C12Q2545/101

Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.